Linked Life Data

12838741

Source:http://linkedlifedata.com/resource/pubmed/id/12838741

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6 Suppl
pubmed:dateCreated
2003-7-3
pubmed:abstractText
Despite significant therapeutic advances in HIV medicine, virologic failures remain frequent in clinical practice. Issues such as suboptimal antiretroviral activity, poor tolerability, inconvenient dosing schedules, long-term toxicity, and low thresholds for the development of resistance all limit the clinical utility of HIV reverse transcriptase and protease inhibitors. Maintaining optimal viral suppression often necessitates that patients change treatment, but drug resistance and cross-resistance can rapidly reduce the number of effective treatments available. On the other hand, the therapeutic success achieved since the introduction of HAART has led to an increased overall exposure to antiretroviral drugs, and new toxicities have emerged. True second-generation agents and agents active against new targets will be essential to maximize the therapeutic impact of current antiretroviral therapy and minimize the risk of resistance development.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
X
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1053-0894
pubmed:author
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S5-9
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Challenges of the unmet needs in the treatment-experienced patient.
pubmed:affiliation
University of British Columbia, Vancouver.
pubmed:publicationType
Journal Article